WuXi Biologics Achieves Continued Recognition in Hang Seng Sustainability Indexes for ESG Leadership

WuXi Biologics Recognized for its ESG Excellence

WuXi Biologics (2269.HK), a prominent player in the Contract Research, Development, and Manufacturing Organization (CRDMO) space, has been reaffirmed in multiple Hang Seng sustainability indexes including the prestigious Hang Seng ESG 50 Index and the Corporate Sustainability Benchmark Index. This recognition not only highlights the company's exemplary environmental, social, and governance (ESG) performance but also strengthens its position in the capital markets.

Since 2014, evaluations by the Hong Kong Quality Assurance Agency (HKQAA) have provided an objective measure of sustainability performance for listed companies, focusing on environmental, social, and governance aspects. These assessments consider various materiality factors unique to different industries and are essential for selecting companies to be included in these sustainability indexes. In 2026, WuXi Biologics achieved an impressive A+ rating from the HKQAA, validating its robust approach to sustainability as integral to long-term business objectives.

WuXi Biologics prioritizes sustainability as a core component of its corporate strategy, aiming to position itself as a Green CRDMO. The company's commitment to green initiatives drives its research, development, and manufacturing practices. By adopting innovative technologies and lean management techniques, WuXi Biologics enhances operational efficiency and integrates digital capabilities into its processes. This strategy not only promotes resource efficiency but also increases the resilience of its operations, facilitating high-quality green practices.

Dr. Chris Chen, CEO of WuXi Biologics, expressed pride in the company’s achievements, stating, “Our ongoing presence in multiple Hang Seng sustainability indexes signifies the recognition of WuXi Biologics' unwavering dedication to sustainability and our Green CRDMO solutions.” He emphasized the belief that sustainability forms a crucial foundation for long-term business growth and acts as a catalyst for innovation and value creation within the industry.

Furthermore, WuXi Biologics has garnered numerous accolades on the international stage for its exemplary sustainability practices. Among its prestigious recognitions are the top MSCI ESG Rating of AAA, the EcoVadis Platinum Medal—placing it in the top 1% globally, and its inclusion in various Dow Jones and FTSE4Good Index series. Such recognitions highlight the company's commitment to balancing profitability with social responsibility and environmental stewardship.

As of June 30, 2026, WuXi Biologics was involved in 1,064 integrated client projects, including 78 in Phase III clinical trials and 28 in commercial manufacturing stages. This impressive portfolio underlines the company’s operational excellence and capacity to manage complex projects effectively.

The company leverages expertise from its workforce of over 14,000 employees across several countries, including China, the US, and Europe. Its strategic focus on embedding technology throughout the biopharmaceutical value chain aims to streamline operations, improve development speed, and deliver more efficient manufacturing solutions.

WuXi Biologics firmly believes that by fostering responsible practices and creating shared value, it can drive positive social and environmental impacts within the biopharmaceutical sector. The firm is resolved to remain a leader in ESG practices and continue its dedication to sustainable development, not just for the business but for the benefit of society and the planet at large.

In summary, WuXi Biologics’ recognition in multiple Hang Seng sustainability indexes marks a significant milestone in its ongoing journey towards sustainable growth. The combination of innovative strategies and deep-rooted commitments toward ESG principles distinguishes WuXi Biologics as an industry leader ready to face the challenges of sustainable development in the future.